Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program 2024-08-22 21:30
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis 2024-07-30 06:00
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade 2024-03-29 06:00
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology 2024-03-27 06:00
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC 2023-10-31 07:00
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis 2023-10-26 07:00
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium 2023-07-12 06:00
Bridge Biotherapeutics to Present at the 2023 BIO International Convention 2023-05-30 06:00
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI 2023-04-24 10:00
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting 2023-04-19 07:00
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis 2023-04-13 06:00
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting 2023-03-15 21:00
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis 2023-02-21 07:00
Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023 2023-01-03 22:00
Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022 2022-09-02 09:41
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877 2022-08-16 08:17
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022 2022-08-10 11:43
Bridge Biotherapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of BBT-176 at the World Conference of Lung Cancer 2022-07-13 06:30
Bridge Biotherapeutics to Present at the 2022 BIO International Convention 2022-05-26 11:02
Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer 2022-05-10 21:00
1 2